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Abstract
In the recent study by Preissig and Rigby in Critical Care, the
authors argue that critical illness hyperglycemia in children with
both respiratory failure and cardiovascular failure is due to a
primary failure of the beta-cell. However, alternative explanations
that the failure is secondary to an increase in insulin resistance
leading to beta-cell exhaustion, or a negative impact of exogenous
glucocorticoid therapy, may be equally likely.
In their study on hyperglycemia in critically ill children Preissig
and Rigby [1] observed that children in the pediatric intensive
care unit are unlikely to have critical illness hyperglycemia
(CIH) in the absence of respiratory failure (RF) or cardio-
vascular failure (CVF) (0 of 12 patients studied), whereas
those with RF but without CVF may (9 of 18) or may not (9 of
18), and virtually all patients with both RF and CVF do (10 of
11). The key observation was that the C-peptide level in
children without CIH was similar for those with RF versus
those without RF or CVF (2.3 versus 5.3 ng/ml), whereas in
children with CIH, C-peptide was significantly higher with RF
alone than with RF and CVF (11.5 versus 4.4 ng/ml; data
reproduced in Figure 1). Importantly, the RF and CVF cohort
uniformly received exogenous glucocorticoid therapy, unlike
the other cohorts (100% versus 44% to 50%). The authors
concluded from their data that elevated insulin resistance
(high C-peptide) was the prominent cause of CIH in children
with RF only, whereas beta-cell dysfunction (low C-peptide)
was the primary cause in children with RF and CVF.
We find the results very interesting but would take care in
concluding that CIH in children with both RF and CVF is due
primarily to a failure of the beta-cell. The beta-cell has a very
complex response to hyperglycemia both acutely (first and
second phase responses over just minutes [2,3]) and over
the course of several days (increased mass [4,5]). Also, beta-
cell exhaustion is a well known phenomenon characterized by
an ability to increase secretion up to a certain level and
thereafter fail in response to further demand [6,7]. Finally,
exogenous glucocorticoid therapy, given to all patients with
RF and CVF together, can also have complex interactions
with insulin secretion, suppressing it in some in vitro studies
[8,9] and enhancing it in other in vivo studies [10,11].
Support for these mechanisms playing a major role in CIH is
variable, but there is insufficient evidence to dismiss the
mechanisms.
Arguments that the beta-cell can rapidly adapt, or become
exhausted, when faced with increased demand provide an
alternative hypothesis to that put forth by Preissig and Rigby.
With adaptation, the difference in C-peptide levels observed
in the RF group without CIH compared to the group that had
neither RF nor CVF (5.3 versus 2.3 ng/ml) could indicate
beta-cell adaptation, with the twofold increase in secretion
having failed to achieve statistical significance due to the
small number of subjects in each group (9 and 12 subjects,
respectively). That the two groups had similar glucose levels
(5.8 versus 6.1 mmol/l) with different secretion (C-peptide)
could occur if the beta-cells’ second phase response is
interpreted as increasing insulin secretion when glucose is
above a threshold [12]. The remaining 9 out of 18 patients
with RF and no CVF may have had CIH only because the
beta-cell did not have sufficient time to normalize the level.
That is, in the study CIH was defined as two blood glucose
values taken 1 to 2 hours apart both above 7.7 mmol/l. This
definition does not preclude the possibility that glucose was
decreasing at the time CIH was assessed. The unarguable
failure of the beta-cell to normalize glucose in children with
RF+CVF could be attributed to beta-cell exhaustion (low
C-peptide levels) secondary to further increases in insulin
resistance in this group. By the authors’ own estimates, the
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RF+CVF subjects required longer, and at times up to 50%
more, exogenous insulin to normalize glucose. Using the
values reported, one could argue that the beta-cell had
sufficient capacity to meet a peak demand of 0.13 U/kg/h for
5.8 days (RF group) but an insufficient capacity to meet a
peak demand of 0.19 U/kg/h for 8.7 days (RF+CVF group).
The clinical entity of RF+CVF represents a temporal and
clinical progression from the state where only one is present -
the key question during this progression being what changes
are occurring in peripheral insulin sensitivity and beta-cell
function. In the authors’ data, the issue becomes whether the
low C-peptide levels in the RF+CVF group are indicative of a
lower level of insulin resistance (Preissig and Rigby’s argu-
ment), or whether the higher exogenous insulin required to
bring these patients to target is indicative of higher resis-
tance. Discerning whether beta-cell exhaustion, or events
secondary to the glucocorticoid therapy, contributed to the
low insulin secretion will be essential in guiding future treat-
ment strategies.
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Figure 1
Blood glucose (BG) and C-peptide (CPEP) levels in children with (+) or
without (-) critical illness hyperglycemia (CIH), with or without respiratory
failure (RF) or cardiovascular failure (CVF). Data taken from [1].